Insider Selling: Alnylam Pharmaceuticals, Inc. (ALNY) CEO Sells 49,457 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO John Maraganore sold 49,457 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $70.00, for a total transaction of $3,461,990.00. Following the transaction, the chief executive officer now owns 239,450 shares in the company, valued at approximately $16,761,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

ALNY stock traded down $1.19 during trading on Friday, reaching $67.54. The stock had a trading volume of 804,786 shares, compared to its average volume of 939,114. Alnylam Pharmaceuticals, Inc. has a one year low of $60.27 and a one year high of $124.21. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.12 and a current ratio of 9.33. The company has a market capitalization of $7.25 billion, a price-to-earnings ratio of -8.92 and a beta of 2.53.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.20) by $0.47. Alnylam Pharmaceuticals had a negative net margin of 929.51% and a negative return on equity of 55.33%. The firm had revenue of $33.29 million during the quarter, compared to the consensus estimate of $21.60 million. During the same period in the prior year, the firm earned ($1.22) EPS. The company’s revenue was up 52.0% compared to the same quarter last year. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -8.48 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in ALNY. Norges Bank bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $94,228,000. Baillie Gifford & Co. grew its position in shares of Alnylam Pharmaceuticals by 19.8% during the 1st quarter. Baillie Gifford & Co. now owns 5,684,504 shares of the biopharmaceutical company’s stock valued at $531,217,000 after acquiring an additional 937,654 shares during the period. FMR LLC grew its position in shares of Alnylam Pharmaceuticals by 5.2% during the 1st quarter. FMR LLC now owns 15,945,666 shares of the biopharmaceutical company’s stock valued at $1,490,122,000 after acquiring an additional 791,113 shares during the period. Wellington Management Group LLP grew its position in shares of Alnylam Pharmaceuticals by 5.4% during the 1st quarter. Wellington Management Group LLP now owns 14,832,598 shares of the biopharmaceutical company’s stock valued at $1,386,107,000 after acquiring an additional 766,371 shares during the period. Finally, Maverick Capital Ltd. grew its position in shares of Alnylam Pharmaceuticals by 14.5% during the 1st quarter. Maverick Capital Ltd. now owns 3,210,387 shares of the biopharmaceutical company’s stock valued at $300,011,000 after acquiring an additional 406,436 shares during the period. 87.89% of the stock is owned by hedge funds and other institutional investors.

ALNY has been the topic of a number of analyst reports. Cowen restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 6th. BidaskClub upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Needham & Company LLC restated a “buy” rating and issued a $135.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, February 8th. Cantor Fitzgerald restated a “buy” rating and issued a $135.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday, February 7th. Finally, Chardan Capital restated a “buy” rating and issued a $150.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, April 9th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and fifteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $130.24.

TRADEMARK VIOLATION WARNING: “Insider Selling: Alnylam Pharmaceuticals, Inc. (ALNY) CEO Sells 49,457 Shares of Stock” was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/05/17/insider-selling-alnylam-pharmaceuticals-inc-alny-ceo-sells-49457-shares-of-stock.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Featured Story: Bar Chart

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.